文献速递MDS 与骨髓增殖性肿瘤白血病

Eprenetapopt联合阿扎胞苷治疗TP53突变MDS与AML的II期研究

Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM).
PubMed 文献 · J Clin Oncol · 2021-02-18

法国骨髓增生异常综合征协作组(GFM)开展II期研究,评估Eprenetapopt(APR-246)联合阿扎胞苷治疗未经治疗的TP53突变高危/极高危MDS与AML患者。MDS的ORR为62%、CR为47%;AML的ORR为33%、CR为17%。MDS中位OS为12.1个月。联合方案总体安全,神经不良事件发生率为40%。

要点

  • MDS的ORR为62%、CR为47%,中位缓解持续时间10.4个月
  • AML的ORR为33%、CR为17%,其中骨髓原始细胞比例超过30%者CR为0%
  • 主要不良事件为发热性中性粒细胞减少(36%)和神经事件(40%),后者可通过暂停用药和减量处理

核心结论

  • 在TP53突变MDS和AML这一极高危人群中,Eprenetapopt联合阿扎胞苷安全,ORR、CR率和OS可能优于单用阿扎胞苷的历史报告。

研究设计与样本

  • II期研究,评估Eprenetapopt联合阿扎胞苷治疗未经治疗的高危或极高危IPSS-R的TP53突变MDS和AML患者。

主要发现

  • MDS中ORR为62%,含47% CR,中位缓解持续时间10.4个月。
  • AML中ORR为33%,含17% CR;骨髓原始细胞比例低于30%和超过30%的AML中CR分别为27%和0%。
  • 中位随访9.7个月时,MDS中位OS为12.1个月;AML骨髓原始细胞比例低于30%和超过30%者中位OS分别为13.9个月和3.0个月。

关键数值与推荐

  • 主要治疗相关不良事件:发热性中性粒细胞减少36%,神经不良事件40%。
  • 神经不良事件与治疗开始时较低的肾小球滤过率(P < .01)和较高年龄(P = .05)相关,暂停用药后可缓解,适当降低Eprenetapopt剂量后未再复发。
  • TP53二代测序阴性定义为变异等位基因频率低于5%。

临床怎么用

  • 对未经治疗的TP53突变高危/极高危MDS和AML,可考虑Eprenetapopt联合阿扎胞苷以提高缓解率。
  • 治疗期间需监测神经不良事件,尤其对高龄或肾小球滤过率较低者,可通过暂停用药和适当减量管理。

局限性

  • 随访时间较短(中位9.7个月),长期生存获益尚不确定。
  • 骨髓原始细胞比例超过30%的AML患者CR为0%,该亚组疗效有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: TP53-mutated (TP53m) myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) have very poor outcome irrespective of the treatment received, including 40% responses (20% complete remission [CR]) with azacitidine (AZA) alone, short response duration, and a median overall survival (OS) of approximately 6 months. Eprenetapopt (APR-246), a novel first-in-class drug, leads to p53 protein reconformation and reactivates its proapoptotic and cell-cycle arrest functions. PATIENTS AND METHODS: This phase II study assessed the safety and efficacy of eprenetapopt in combination with AZA in untreated high or very high International Prognostic Scoring System-R TP53m MDS and AML patients. RESULTS: Fifty-two TP53m patients (34 MDS, 18 AML [including seven with more than 30% blasts]) were enrolled. In MDS, we observed an overall response rate (ORR) of 62%, including 47% CR, with a median duration of response at 10.4 months. In AML, the ORR was 33% including 17% CR (27% and 0% CR in AML with less than and more than 30% marrow blasts, respectively). Seventy-three percent of responders achieved TP53 next-generation sequencing negativity (ie, variant allele frequency < 5%). The main treatment-related adverse events were febrile neutropenia (36%) and neurologic adverse events (40%), the latter correlating with a lower glomerular filtration rate at treatment onset (P < .01) and higher age (P = .05), and resolving with temporary drug interruption without recurrence after adequate eprenetapopt dose reduction. With a median follow-up of 9.7 months, median OS was 12.1 months in MDS, and 13.9 and 3.0 months in AML with less than and more than 30% marrow blasts, respectively. CONCLUSION: In this very high-risk population of TP53m MDS and AML patients, eprenetapopt combined with AZA was safe and showed potentially higher ORR and CR rate, and longer OS than reported with AZA alone.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Cluzeau T, Sebert M, Rahmé R, et al. Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM). J Clin Oncol. 2021. PMID: 33600210. doi:10.1200/JCO.20.02342

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。